Equities researchers at HC Wainwright increased their FY2026 earnings estimates for shares of Oncolytics Biotech in a ...

Investment analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for Cidara Therapeutics in a report ...

H.C. Wainwright lowered the firm’s price target on Vigil Neuroscience (VIGL) to $14 from $17 and keeps a Buy rating on the shares ahead of ...

H.C. Wainwright lowered the firm’s price target on Cartesian Therapeutics (RNAC) to $40 from $45 and keeps a Buy rating on the shares. The firm ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

Quantum computing continues to advance rapidly, which has been helping businesses get new opportunities related to security, ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Discover how Bit Digital's Q4 2024 results showcase a 141% revenue increase, a strategic shift to HPC with WhiteFiber, and a strong pipeline for ...

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at ...

U.S. stocks were higher, with the Dow Jones index gaining around 1% on Friday. Shares of Semtech Corporation SMTC rose ...

Welcome to the Aemetis fourth-quarter and year-end 2024 earnings review conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce ...

Please go ahead. Good afternoon and thank you for joining us today. Earlier this afternoon, REGENXBIO released financial and operating results for the fourth-quarter and year ending December 31, 2024.